Autopsy report · NCT03131206
A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
Cause of deathSlow enrollment, also futility
“Study closed due to slow accrual and lack of efficacy.”
Life of this trial
- Registered 2 months before it started.
- Ran for about 1 year 10 months before it stopped.
- 5 participants enrolled.
- Results were posted on the registry 8 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Dana-Farber Cancer Institute
- Sponsor type
- University, hospital or other
- Conditions
- ALK-positive Non-small Cell Lung Cancer (NSCLC); RET-positive Non-small Cell Lung Cancer (NSCLC); RET-positive Thyroid Cancer
- Interventions
- Alectinib
- Participants
- 5
- Sites
- 4
- Countries
- United States
Trials that died the same way
- Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
“Study was closed to low accrual.” - S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery
“This study was closed early due to poor accrual” - High Dose Rate Brachyablation of Primary Liver Lesions
“Study was closed due to poor accrual” - Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
“Study stopped due to lack of efficacy.” - Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer
“Study was terminated early due to a lack of improved efficacy.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.